These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 9599303)

  • 1. Acquired salivary dysfunction. Drugs and radiation.
    Fox PC
    Ann N Y Acad Sci; 1998 Apr; 842():132-7. PubMed ID: 9599303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiation-induced xerostomia: pathophysiology, clinical course and supportive treatment.
    Guchelaar HJ; Vermes A; Meerwaldt JH
    Support Care Cancer; 1997 Jul; 5(4):281-8. PubMed ID: 9257424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetics of tempol for prevention of xerostomia following head and neck irradiation in a mouse model.
    Cotrim AP; Sowers AL; Lodde BM; Vitolo JM; Kingman A; Russo A; Mitchell JB; Baum BJ
    Clin Cancer Res; 2005 Oct; 11(20):7564-8. PubMed ID: 16243832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of head and neck radiotherapy on major salivary glands--animal studies and human implications.
    Nagler RM
    In Vivo; 2003; 17(4):369-75. PubMed ID: 12929593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TAT-mediated delivery of Tousled protein to salivary glands protects against radiation-induced hypofunction.
    Sunavala-Dossabhoy G; Palaniyandi S; Richardson C; De Benedetti A; Schrott L; Caldito G
    Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):257-65. PubMed ID: 22285666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Possible role of nitric oxide in radiation-induced salivary gland dysfunction.
    Takeda I; Kizu Y; Yoshitaka O; Saito I; Yamane GY
    Radiat Res; 2003 Apr; 159(4):465-70. PubMed ID: 12643791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral pilocarpine: a review of its pharmacological properties and clinical potential in xerostomia.
    Wiseman LR; Faulds D
    Drugs; 1995 Jan; 49(1):143-55. PubMed ID: 7705213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of pilocarpine during head and neck radiation therapy to reduce xerostomia and salivary dysfunction.
    Valdez IH; Wolff A; Atkinson JC; Macynski AA; Fox PC
    Cancer; 1993 Mar; 71(5):1848-51. PubMed ID: 8448748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiation-induced salivary dysfunction: clinical course and significance.
    Valdez IH
    Spec Care Dentist; 1991; 11(6):252-5. PubMed ID: 1813995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of post-radiotherapy salivary glands.
    Cheng SC; Wu VW; Kwong DL; Ying MT
    Br J Radiol; 2011 May; 84(1001):393-402. PubMed ID: 21511748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1 clinical study of cell therapy with effective-mononuclear cells (E-MNC) for radiogenic xerostomia (first-in-human study) (FIH study on E-MNC therapy for radiogenic xerostomia).
    Sumita Y; Iwamoto N; Seki M; Yoshida T; Honma R; Iwatake M; Ohba S; Takashi I; Hotokezaka Y; Harada H; Kuroshima S; Nagai K; Asahara T; Atsushi Kawakam I; Asahina I
    Medicine (Baltimore); 2020 Jun; 99(26):e20788. PubMed ID: 32590759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Assessment of radiation injuries to the salivary glands after treatment of head and neck cancers].
    Urban A; Miszczyk L; Maciejewski B
    Otolaryngol Pol; 2005; 59(1):21-5. PubMed ID: 15915914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pilocarpine in the prevention of postirradiation xerostomia.
    Lajtman Z; Krajina Z; Krpan D; Vincelj J; Borcić V; Popović-Kovacić J
    Acta Med Croatica; 2000; 54(2):65-7. PubMed ID: 11028111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current therapies for xerostomia and salivary gland hypofunction associated with cancer therapies.
    Nieuw Amerongen AV; Veerman EC
    Support Care Cancer; 2003 Apr; 11(4):226-31. PubMed ID: 12673460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancer.
    Thorstad WL; Chao KS; Haughey B
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):8-12. PubMed ID: 15726516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural history and prevention of radiation injury.
    O'Connell AC
    Adv Dent Res; 2000 Dec; 14():57-61. PubMed ID: 11842925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salivary gland function and xerostomia in southern Chinese following radiotherapy for nasopharyngeal carcinoma.
    Pow EH; McMillan AS; Leung WK; Wong MC; Kwong DL
    Clin Oral Investig; 2003 Dec; 7(4):230-4. PubMed ID: 12955605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Xerostomia: recognition and management of hypofunction of the salivary glands.
    Garg AK; Kirsh ER
    Compend Contin Educ Dent; 1995 Jun; 16(6):574, 576-84; quiz 586. PubMed ID: 8620388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathophysiology and management of radiation-induced xerostomia.
    Berk LB; Shivnani AT; Small W
    J Support Oncol; 2005; 3(3):191-200. PubMed ID: 15915820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dramatic and prolonged decrease of whole salivary secretion in nasopharyngeal carcinoma patients treated with radiotherapy.
    Jen YM; Lin YC; Wang YB; Wu DM
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2006 Mar; 101(3):322-7. PubMed ID: 16504865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.